Sorafenib in Advanced Hepatocellular Carcinoma
2008 · New England Journal of Medicine · 13K citations
https://doi.org/10.1056/nejmoa0708857
J
Jordi Bruix
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
705
Papers
128.0K
Citations
128
h-index
349
i10-index
Jordi Bruix is an academic researcher from Centre for Biomedical Network Research on Rare Diseases. The author has contributed to research in topics: Hepatocellular Carcinoma Treatment and Prognosis & Liver Disease Diagnosis and Treatment & Liver Disease and Transplantation. The author has an h-index of 128, co-authored 600 publications.
ORCID: 0000-0002-9826-0753Papers by this author
worksHepatocellular carcinoma
2012 · The Lancet · 4,009 citations
https://doi.org/10.1016/s0140-6736(11)61347-0
BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update
2021 · Journal of Hepatology · 3,880 citations
https://doi.org/10.1016/j.jhep.2021.11.018
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
2016 · The Lancet · 3,590 citations
https://doi.org/10.1016/s0140-6736(16)32453-9
Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival
2003 · Hepatology · 2,997 citations
https://doi.org/10.1053/jhep.2003.50047
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
2020 · Nature Reviews Gastroenterology & Hepatology · 2,374 citations
https://doi.org/10.1038/s41575-020-0310-z
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat